Fernandez-Barrena: Nothing to Disclose, Laura Alvarez: Nothing to Disclose, Colm O'Rourke: Nothing to Disclose, Pui-Yuen Lee-Law: Nothing to Disclose, Kyle Davies: Nothing to Disclose, Andreea Gradinaru: Nothing to Disclose, Raul Jimenez-Aguero: Nothing to Disclose, Adelaida La Casta: Nothing to Disclose, Ioana Riao: Nothing to Disclose, Rocio Macias: Nothing to Disclose, Jose J G Marin: Nothing to Disclose, Maria L Martinez-Chantar: Nothing to Disclose, Matias A Avila: Nothing to Disclose, Patricia Aspichueta: Nothing to Disclose, Jesper B Andersen: Nothing to Disclose, Luke Boulter: Nothing to Disclose, Luis Bujanda: Nothing to Disclose, Pedro M Rodrigues: Nothing to Disclose, Maria J Perugorria: Nothing to Disclose, Jesus M Banales: Nothing to Disclose 1936 THE INVOLVEMENT OF MICRORNA-1297 IN LENVATINIB RESISTANCE IN HEPATOCELLULAR CARCINOMA CELLS Takayuki Kogure 1 Mari Satoh 1 Takehito Ito 1 Kennichi Satoh 1 , 1 Tohoku Medical and Pharmaceutical University Background: Lenvatinib for treating hepatocellular carcinoma (HCC) has a superior response rate, although its overall survival is non-inferior to sorafenib, suggesting tumor cells may acquire resistance during therapy
Semaglutide and tirzepatide are powerful tools for weight loss, but they work best when your body is fully supported
P -trend =0.04), but not cancer mortality overall and in stratified analysis by Mg intake level
Does semaglutide affect kidney function
2.3 GLP-1R activation reduces alcohol drinking in overweight patients with AUD Although numerous preclinical studies have revealed that activation of the GLP-1 pathway suppresses alcohol-related responses, only a handful of clinical studies have explored this interaction in humans
Coronary thermodilution to assess flow reserve: experimental validation
